| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 405.91 | 5.4% | 25.8% |
| Total Income | 414.93 | 3.5% | 27.5% |
| Expenditure | 348.67 | 2.9% | 23.2% |
| PBT | 57.16 | 19.5% | 35.0% |
| Net Profit | 42.09 | 20.4% | 33.7% |
| OPM | 21.13% | 4.09pp | 18.79pp |
| NPM | 10.14% | 2.16pp | 0.47pp |
| EPS | 7.99 | 21.4% | 30.8% |
Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63%
04 Feb 2026 · 4 Feb, 5:42 pm
Summary
Metropolis Healthcare Limited, India’s second-largest and most trusted pathology laboratory chain, announced its unaudited consolidated financial results for the quarter ended December 31, 2026 (Q3FY26). The company reported a 26% YoY increase in revenue and a 63% YoY surge in PAT. Patient and test volumes grew 14% and 13% YoY, respectively. B2C revenues grew 19% YoY and B2B revenues grew ~35% YoY. TruHealth and Specialty portfolios recorded strong growth of ~37% and ~34% YoY, respectively. North India’s revenue contribution was at 17%, while Tier III cities registered 16% revenue growth and contributed 24% to overall revenues.
Key Highlights
- 1
Revenue: ₹406 Crore, +26% YoY
- 2
EBITDA: ₹95 Cr, +32% YoY
- 3
PAT: ₹51 Cr, +63% YoY
- 4
Patient and Test Volumes grew 14% and 13% YoY
- 5
B2C revenues grew 19% YoY, B2B revenues grew ~35% YoY
- 6
TruHealth and Specialty portfolios recorded strong growth of ~37% and ~34% YoY
- 7
North India’s revenue contribution at 17%
- 8
Tier III cities registered 16% revenue growth and contributing 24% to overall revenues
Management Comments
Ameera Shah
Comment not provided in the document.
Informational and educational content only. Not investment advice.